Spherix study: Access barriers curb Xphozah uptake ahead of TDAPA cliff
Spherix Global Insights reports that access barriers, not efficacy, limit Ardelyx's Xphozah adoption in the dialysis hyperphosphatemia market. Physicians state they would nearly triple usage if reimbursement hurdles were removed. The findings highlight a perception gap where doctors overestimate treatment aggression and phosphate control among patients.
*this image is generated using AI for illustrative purposes only.
Access barriers, rather than clinical efficacy, remain the primary constraint on Ardelyx's Xphozah (tenapanor) adoption in the US dialysis hyperphosphatemia market, according to new cross-study analysis from Spherix Global Insights. Published on July 29, 2026, the findings indicate that nephrologists would nearly triple their use of Xphozah if reimbursement and coverage obstacles were eliminated. This insight is critical for investors and market access stakeholders as the Transitional Drug Add-on Payment Adjustment (TDAPA) expires at the end of 2026, a shift expected to flatten reimbursement differentials across oral phosphate binders.
The data reveals a significant disconnect between physician intent and real-world prescribing behavior. While four in ten nephrologists cite renewed dietary counseling as their first response to persistent phosphorus elevation, fewer than one in ten add Xphozah as combination therapy. Despite this, nearly half of physicians now report increasing use of combination phosphate-lowering therapy overall, up nearly 20 percentage points from a year earlier, as they layer agents to reach targets. However, many patients who remain well above target continue on binder monotherapy or receive no phosphate-lowering therapy at all, underscoring a persistent gap between available treatment options and therapeutic escalation.
Perception Gaps in Treatment Aggression
A parallel analysis of patient chart data exposes a meaningful divergence between physician estimates and actual clinical practice. Nephrologists estimate that roughly one-third of treated hyperphosphatemia patients receive combination therapy; however, Spherix’s audit of 1,033 dialysis patient charts shows the actual figure is closer to one in seven.
This misjudgment extends to disease control assessments. When physicians deem a patient 'well controlled' and unlikely candidates for Xphozah, chart data reveals that one in eight of those patients were actually above target at their last phosphorus measurement. Overall, one-third of treated patients remained above historical phosphorus targets at their most recent laboratory assessment, while nearly two-thirds exceeded target at least once during the previous six months.
The Role of Renal Dietitians
Influence over treatment decisions is shifting toward renal dietitians. A separate Spherix study of 100 renal dietitians found that nearly nine in ten report greater involvement than nephrologists in managing hyperphosphatemia. More than half of nephrologists corroborate this, reporting significant dietitian influence on decisions to add or switch therapies.
Economic pressures heavily shape these recommendations. Approximately one-third of dietitians frequently recommend alternative prescriptions due to patient out-of-pocket costs or insurance denials. Treatment preferences also diverge by stakeholder: while dietitians most often favor Velphoro (sucroferric oxyhydroxide), nephrologists identify Xphozah as their preferred therapy if access barriers were removed, though neither preference reaches a majority.
Xphozah Utilization and Persistence Challenges
Xphozah currently reaches approximately one in ten dialysis patients, with nearly two-thirds of current users initiating the therapy within six months of starting dialysis. Among all phosphate-lowering agents evaluated, Xphozah produced the largest reduction in serum phosphorus following initiation, driven by its efficacy, lower pill burden, and differentiated mechanism of action.
However, persistence remains a distinct commercial challenge. The proportion of patients who initiated and later discontinued Xphozah doubled over the past year, increasing from 4% to 8%. Gastrointestinal tolerability was cited as the leading reason for discontinuation.
What the Numbers Show
The data highlights a dual-market dynamic for Ardelyx. On one hand, Xphozah demonstrates superior clinical efficacy in reducing serum phosphorus, particularly in treatment-resistant cases. On the other hand, its market penetration is artificially suppressed by external payer friction (formulary restrictions, prior authorizations) and internal cognitive biases among prescribers who underestimate uncontrolled phosphorus levels. As TDAPA expires, the removal of economic differentiators may force a re-evaluation of these access barriers, potentially benefiting therapies with strong efficacy profiles like Xphozah if payer policies adapt accordingly.
| Metric | Physician Estimate | Actual Chart Data |
|---|---|---|
| Combination Therapy Usage | ~33% (one-third) | ~14% (one in seven) |
| 'Well Controlled' Patients Above Target | Not specified | 12.5% (one in eight) |
| Patients Above Target (Recent Lab) | Not specified | 33% (one-third) |
| Patients Above Target (Last 6 Months) | Not specified | ~66% (nearly two-thirds) |
Kari McCarthy, Head of Nephrology at Spherix Global Insights, noted that Xphozah faces two distinct challenges: uptake constrained by formulary restrictions and physician perception gaps, and persistence limited by gastrointestinal tolerability. "One challenge is external to the product; the other reflects the treatment experience itself," McCarthy said.
The commercial landscape is set to evolve significantly as the Medicare ESRD bundle absorbs reimbursement for six oral phosphate binders—including Velphoro, Auryxia, Fosrenol, Renvela, Renagel, and calcium acetate—previously covered under TDAPA. Ardelyx’s Xphozah entered the bundle via a different pathway without TDAPA, but the market is moving toward a unified reimbursement structure that no longer meaningfully differentiates phosphate-lowering therapies economically.
How might Ardelyx adjust its commercial strategy to mitigate the impact of the TDAPA expiration and the resulting flattening of reimbursement differentials across phosphate binders?
What specific interventions could Ardelyx implement to address the 8% discontinuation rate driven by gastrointestinal tolerability issues?
Given the significant influence of renal dietitians on prescribing decisions, how is Ardelyx planning to engage this stakeholder group to counter their preference for Velphoro?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
